1. Home
  2. GATX vs RYTM Comparison

GATX vs RYTM Comparison

Compare GATX & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GATX Corporation

GATX

GATX Corporation

HOLD

Current Price

$178.96

Market Cap

6.2B

ML Signal

HOLD

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$106.39

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GATX
RYTM
Founded
1898
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Transportation Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.2B
5.8B
IPO Year
1994
2017

Fundamental Metrics

Financial Performance
Metric
GATX
RYTM
Price
$178.96
$106.39
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
14
Target Price
$215.50
$131.14
AVG Volume (30 Days)
210.6K
872.9K
Earning Date
05-07-2026
05-05-2026
Dividend Yield
1.36%
N/A
EPS Growth
17.22
28.34
EPS
2.35
N/A
Revenue
$1,740,400,000.00
N/A
Revenue This Year
$42.21
$55.34
Revenue Next Year
$3.35
$86.06
P/E Ratio
$75.80
N/A
Revenue Growth
9.77
N/A
52 Week Low
$148.20
$74.50
52 Week High
$205.56
$122.20

Technical Indicators

Market Signals
Indicator
GATX
RYTM
Relative Strength Index (RSI) 52.72 52.16
Support Level $166.38 $98.30
Resistance Level $183.47 $113.51
Average True Range (ATR) 4.86 4.15
MACD 0.24 -1.46
Stochastic Oscillator 73.90 14.40

Price Performance

Historical Comparison
GATX
RYTM

About GATX GATX Corporation

GATX Corp leases transportation assets, including railcars, aircraft spare engines, and tank containers, to customers in North America, Europe, and India. The company's reportable business segments are: Rail North America, Rail International, Engine Leasing, and Other. The majority of its revenue is generated from the Rail North America segment, which is composed of the company's operations in the United States, Canada, and Mexico. This segment mainly provides railcars pursuant to full-service leases under which it maintains the railcars, pays ad valorem taxes and insurance, and provides other ancillary services.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: